Ipilimumab 200 MG in 40 ML Injection

DRUG3 trials

Sponsors

GERCOR - Multidisciplinary Oncology Cooperative Group, Hospital Israelita Albert Einstein

Conditions

Localized Oesogastric AdenocarcimonaMSI and or dMMRMetastatic Cancer ColorectalUterine Cervical Neoplasms

Phase 2

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active, not recruitingNCT03350126

GERCOR - Multidisciplinary Oncology Cooperative GroupMetastatic Cancer Colorectal

Start: 2017-12-04End: 2025-12-31Updated: 2025-07-23

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Active, not recruitingNCT04006262

GERCOR - Multidisciplinary Oncology Cooperative GroupLocalized Oesogastric Adenocarcimona, MSI and or dMMR

Start: 2019-10-23End: 2025-10-31Target: 32Updated: 2025-06-15

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

RecruitingNCT05492123

Hospital Israelita Albert EinsteinUterine Cervical Neoplasms

Start: 2022-08-30End: 2028-03-31Target: 112Updated: 2024-01-05

Related Papers

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for women with locally advanced cervical cancer.

Journal of Clinical Oncology2025-05-28

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study

Journal for ImmunoTherapy of Cancer2025-05-013 citations

Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology2025-01-271 citations

Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.

2023-06-0132 citations

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Journal of Clinical Oncology2022-08-15334 citations

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

Journal of Clinical Oncology2022-01-1951 citations

One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.

Journal of Clinical Oncology2022-01-1919 citations

Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.

2021-05-1342 citations

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Journal for ImmunoTherapy of Cancer2020-11-0177 citations

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

2020-02-1013 citations

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.

Journal of Clinical Oncology2020-02-011 citations